Different sensitivity of rituximab-treatment to B-cells between ABO-incompatible kidney and liver transplantation
Different sensitivity of rituximab-treatment to B-cells between ABO-incompatible kidney and liver transplantation
复制标题
DOI：
10.1016/j.humimm.2016.04.013
复制
发表时间：
2016-06-01
期刊：
影响因子：
2.7
通讯作者：
Ohdan, Hideki
中科院分区：
文献类型：
--
作者：
Morimoto, Hiroshi;Ide, Kentaro;Ohdan, Hideki
利妥昔单抗的脱敏方案目前广泛用于跨越ABO血型不相容（ABO-I）屏障的肾移植（KT）和肝移植（LT）。然而，利妥昔单抗是否对KT和LT受体的B细胞和T细胞免疫应答同样有效仍有待阐明。为了阐明利妥昔单抗的这些作用，我们在这项研究中招募了46名KT和77名LT接受者。在围手术期测定外周血B细胞的比例。通过混合淋巴细胞反应（MLR）试验评价T细胞对同种异体刺激的反应。利妥昔单抗给药后一周，外周血B细胞在ABO-I KT受体中检测不到，但在一些ABO-I LT受体中仍可检测到;到第2周，两组中均检测不到B细胞。在ABO-I KT受体中，B细胞在整个第一年保持低于检测限，而在ABO-I LT受体中，它们在6个月后再次出现在外周。基于ABO-I和ABO相容组之间的MLR分析，同种异体反应性T细胞应答无显著差异。这项研究表明，利妥昔单抗有不同的KT和LT受体之间的B细胞敏感性和同种异体反应性T细胞反应在KT和LT受体的影响最小。(C)2016年美国组织相容性和免疫遗传学学会。爱思唯尔公司出版All rights reserved.
A desensitization protocol with rituximab is currently widely used for kidney transplantation (KT) and liver transplantation (LT) across the ABO blood group-incompatible (ABO-I) barrier. However, it remains to be elucidated whether rituximab is equally effective for B-cell and T-cell immune responses in both KT and LT recipients. To clarify these effects of rituximab, we enrolled 46 KT and 77 LT recipients in this study. The proportion of peripheral blood B-cells was determined at the perioperative period. T-cell responses to allostimulation were evaluated by a mixed lymphocyte reaction (MLR) assay. One week after rituximab administration, peripheral B-cells became undetectable in ABO-I KT recipients but remained detectable in some of the ABO-I LT recipients; B-cells were undetectable in both groups by week 2. B-cells remained below the detection limit throughout the first year in the ABO-I KT recipients, whereas they reappeared in the periphery after 6 months in the ABO-I LT recipients. There were no significant differences in alloreactive T-cell responses based on MLR analyses between ABO-I and ABO-compatible groups. This study indicates that rituximab has differing B-cell sensitivity between KT and LT recipients and a minimal effect on the alloreactive T-cell responses in KT and LT recipients. (C) 2016 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.